Clinical trials: Gastric Diseases
Stomach Neoplasms
Irinotecan as 3rd Line Therapy in Gastric Cancer
Gastric cancer is the leading cause of cancer death in China. Most patients are unresectable or metastatic disease at the time of diagnosis. Systemic therapy was required for the patients with advanced stage.
- Trial name
- NCT02662959
- Testing
- Irinotecan
- Where
- China
- Volunteers
- 93 people
- Sponsor
- Fudan University
Gastric Cancer
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor
Assess whether the combination of ABT-888 with FOLFIRI has activity in subjects with gastric cancer.
- Trial name
- NCT01123876
- Testing
- Veliparib
- Where
- 8 sites in United States, South Korea
- Volunteers
- 60 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Iron Deficiency Anemia Secondary to IBD or Gastric Bypass
Treatment Response of Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD) or Gastric Bypass
The primary objective of this study is to evaluate the treatment response of Injectafer vs. oral iron to baseline hepcidin levels to determine if any of these select IBD or Gastric Bypass patients may demonstrate to be…
- Trial name
- NCT02086968
- Testing
- Injectafer, Ferrous Sulfate tablets
- Volunteers
- 198 people
- Sponsor
- American Regent, Inc.
Obesity, Diabetes
The Effect of Macronutrients in the Diet on Digestive and Cardiovascular Health
This study examined the effect of a 5-day HFD supplemented with specific fatty acids on gastrointestinal transit, appetite, food intake and substrate utilization.
- Conditions
- Obesity, Diabetes, Cardiovascular Diseases
- Trial name
- NCT01510223
- Testing
- Olive oil, Olive oil and fish powder, Olive oil and macadamia oil
- Where
- Ireland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Limerick
Diabetes Mellitus, Non-Insulin-Dependent
Effect of Laparoscopic Roux-en-Y Gastric Bypass Surgery on Non-severe Obesity With Type 2 Diabetes Mellitus
The effect of roux-en-Y gastric bypass(RYGB) on patients with type 2 diabetes mellitus(T2DM) and a body mass index(BMI)>35kg/m2 is clear.
- Trial name
- NCT02091323
- Testing
- gastric bypass surgery
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Guangzhou General Hospital of Guangzhou Military Command
Gastric Cancer
The First-line Combined Chemotherapy for Advanced Gastric Cancer: A Prospective Observational Clinical Study
This prospective cohort study aims to observe the efficacy and safety of the first-line combined chemotherapy for advanced gastric cancer(AGC) in Chinese population.
- Trial name
- NCT02583659
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Huazhong University of Science and Technology
Recurrent/Metastatic Gastric Cancer
Study of M7824 and Paclitaxel Combination as a Second-line Treatment in Patients With Recurrent/Metastatic Gastric Cancer
This is a Phase 1b/2 study to identify the recommended dose of M7824 for further study with weekly paclitaxel, and to assess the safety and clinical efficacy of this combined treatment in advanced gastric cancer after first line…
- Trial name
- NCT04835896
- Testing
- M7824+paclitaxel
- Where
- South Korea
- Volunteers
- 49 people
- Sponsor
- Yonsei University
HER2-positive Breast Cancer, HER2 Low
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
This is an open-label, single-arm, multi-site phase I/Ib trial with SYD985, an antibody-drug conjugate (ADC) targeting HER2 on the cell membrane, combined with paclitaxel.
- Conditions
- HER2-positive Breast Cancer, HER2 Low, SYD-985, SYD985
- Trial name
- NCT04602117
- Testing
- Vic-trastuzumab duocarmazine (SYD985) + paclitaxel
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- QuantumLeap Healthcare Collaborative
Pancreatic Disease, Pancreatic Cancer
The Effectiveness of Adding Braun Anastomosis to Standard Child Reconstruction After Pancreatoduodenectomy
The goal of this clinical trial (REMBRANDT) is to evaluate the effectiveness of adding an extra connection (i.e. 'Braun anastomosis') after standard reconstruction in pancreatic head resection in reducing the incidence of delayed…
- Conditions
- Pancreatic Disease, Pancreatic Cancer, Delayed Gastric Emptying
- Trial name
- REMBRANDT (NCT05709197)
- Testing
- Braun anastomosis, Standard Child reconstruction
- Where
- 12 sites in Netherlands
- Volunteers
- 256 people
- Sponsor
- Radboud University Medical Center
Gastroparesis, Functional Dyspepsia
Prokinetics and Body Surface Gastric Mapping in Dyspeptic Patients: Baseline and Treatment Effects
Functional dyspepsia and gastroparesis are common stomach disorders with symptoms like early satiety, nausea, and abdominal pain, and are often evaluated with gastric emptying tests, although the correlation with symptoms is…
- Trial name
- NCT06854120
- Testing
- Gastric Alimetry
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 125 people
- Sponsor
- University of Auckland, New Zealand
Gastric Cancers
The Association Between Microplastics and Macrogenomics and Metabolomics in Gastric Cancer
The aim of this study was to identify and quantify microplastics in blood, stool, and tumor surgical specimens from gastric cancer patients by analyzing the nature, type, and abundance of microplastics using laser direct infrared…
- Trial name
- NCT06856382
- Testing
- gastric cancer
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Dong Peng
Gastrooesophageal Cancer
Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer
Multicentre, single arm, open label UK phase II trial to assess the efficacy of trastuzumab deruxtecan in reducing micrometastatic disease burden in HER2 positive GOA patients who are ctDNA positive after chemotherapy and…
- Trial name
- DECIPHER (NCT05965479)
- Testing
- Trastuzumab deruxtecan
- Where
- 14 sites in United Kingdom
- Volunteers
- 25 people
- Sponsor
- University of Southampton
Gastric Cancer
Combination Chemotherapy as First-Line Therapy in Treating Patients With Stage IV Gastric Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as floxuridine, leucovorin, oxaliplatin, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00448682
- Testing
- Docetaxel, Floxuridine, Leucovorin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Miami
Gastro-enteropancreatic Neuroendocrine Tumor, Pancreatic Cancer
FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
The purpose of this study is evaluate the efficacy and safety of FOLFIRINOX in patients with gastroenteropancreatic high-grade neuroendocrine carcinomas.
- Conditions
- Gastro-enteropancreatic Neuroendocrine Tumor, Pancreatic Cancer, Neuroendocrine Carcinomas of Pancreas, Islet Cell Carcinoma
- Trial name
- NCT03042780
- Testing
- FOLFIRINOX, Granulocyte colony-stimulating factor (G-CSF)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Immunotherapy, Gastric Cancer
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
immunotherapy，gastric cancer，rectal cancer，biomark
- Conditions
- Immunotherapy, Gastric Cancer, Rectal Cancer, Chemotherapy Effect
- Trial name
- NCT05515796
- Testing
- Terelizumab (aka Tislelizumab), CapeOx, Trastuzumab
- Where
- China
- Volunteers
- 189 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Sentinel Lymph Node, Early Gastric Cancer
Feasibility Study of Sentinel Navigation Surgery After Non-curative Endoscopic Resection
Purpose: To prove the feasibility of sentinel node navigation surgery (SNNS) in early gastric cancer patients with the risk of lymph node metastasis after endoscopic resection and preparation of multicenter phase 3 trial of…
- Trial name
- SENORITA2 (NCT03123042)
- Testing
- Sentinel basin dissection
- Where
- 9 sites in South Korea
- Volunteers
- 243 people
- Sponsor
- National Cancer Center, Korea
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy…
- Conditions
- GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors
- Trial name
- ACTION-1 (NCT05477576)
- Testing
- RYZ101, Everolimus, Sunitinib
- Where
- 54 sites in United States, Belgium and 6 more
- Volunteers
- 343 people
- Sponsor
- RayzeBio, Inc.
Obesity and Obesity-related Medical Conditions
Bariatric Surgery vs. Semaglutide vs. Tirzepatide
The recent introduction of the new generation of anti-obesity medications (AOMs) will change the future of obesity treatment. These highly effective medications, such as high-dose semaglutide and tirzepatide, are hormone…
- Trial name
- NCT06803888
- Testing
- Bariatric Surgery, Semaglutide, Tirzepatide
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Ali Aminian
Anal Cancer, Colorectal Cancer
Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Anal Cancer, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer
- Trial name
- NCT00003427
- Testing
- irinotecan hydrochloride, oxaliplatin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Atrophic Gastritis
Atrophic Gastritis Predicts the Risk of Gastric Cancer
Despite declining incidence rates, gastric cancer (GC) ranks the fourth leading cause of cancer-related mortality and the fifth most common cancer worldwide, with the highest incidence reported in Eastern Asia.
- Trial name
- NCT06203327
- Testing
- Esophagogastroscopy (OLGA 0-Ⅰ), Esophagogastroscopy (OLGA II), Esophagogastroscopy (OLGA III-IV)
- Where
- China
- Volunteers
- 2,042 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.